Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancing recovery in early schizophrenia – cannabidiol vs placebo add-on
DRKS00011151Phase 2Recruiting
- Sponsor
- Central Institute of Mental Health
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Cannabidiol add-on with Placebo add-on (2 arms). Started Oct 2016; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on DRKS00011151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011151.